Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin's lymphoma

Folia Histochemica et Cytobiologica

Volumn 49, Issue 2, 2011, Pages 240-247

  Mazur, Grzegorz ^a   Jaskula, Emilia ^b   Kryczek, Ilona ^b   Dlubek, Dorota ^b   Butrym, Aleksandra ^a   Wróbel, Tomasz ^a   Lange, Andrzej ^b   Kuliczkowski, Kazimierz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Chemokines; Gene expression; Lymphoma

Indexed keywords

CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; AUTACOID;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; INFLAMMATION; LYMPH NODE; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; SURVIVAL TIME; T CELL LYMPHOMA; ADOLESCENT; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION MEDIATORS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 80055088660     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0033     Document Type: Article

References (48)

1. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev. 2001;4:313-335.
2. Paoletti S, Petkovic V, Sebastiani S et al. A rich chemokine environment strongly enhances leukocyte migration and activities. Blood. 2005;105:3405-3412.
3. de Gorter DJ, Beuling EA, Kersseboom R et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity. 2007;26:93-104.
4. Kakinuma T, Hwang ST. Chemokines, chemokine receptors and cancer metastasis. J Leukocyt Biol. 2006;79:639-651.
5. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127.
6. Laurence AD. Location, movement and survival: the role of chemokines in hematopoiesis and malignancy. Br J Haematol. 2006;132:255-267.
7. Marafioti T, Hummel M, Foss HD et al. Hodgkin and Reed- -Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95:1443-1450.
8. Maggio E, van den Berg A, Diepstra A et al. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol. 2002;13:(Suppl 1):52-56.
9. Buri C, Körner M, Schärli P et al. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the non-neoplastic leukocytic infiltrates of Hodgkin disease. Blood. 2001;97:1543-1548.
10. Poppema S, van den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol. 2000;10:345-350.
11. Marshall NA, Christie LE, Munro LR et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood. 2004;103:1755-1762.
12. Moore MA. The role of chemoattraction in cancer metastases. Bioassays. 2001;23: 674-676.
13. Lopez-Giral S, Quintana NE, Cabrerizo M et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol. 2004;76:1-9.
14. Moldobaeva A, Baek A, Eldridge L et al. Differential activity of pro-angiogenic CXC chemokines. Microvasc Res. 2010; doi.org/10.1016/j.mvr.2010.01.011.
15. Mazur G, Jaskuła E, Kryczek I. Udział chemokin w chorobach nowotworowych. Adv Clin Exp Med. 2004;13:315-325.
16. Kim CH. The greater chemotactic network for lymphocyte trafficking: chemokines and beyond. Curr Opin Hematol. 2005;12:298-304.
17. Złotnik A. Chemokines in cancer progression. Semin Cancer Biol. 2004;14:181-185.
18. Trentin L, Cabrelle A, Facco M et al. Homeostatic chemokines drive migration of malignant B cells in patients with non- -Hodgkin lymphomas. Blood. 2004;104:502-508.
19. Corcione A, Arduino N, Ferretti E et al. CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clin Cancer Res. 2004;10:964-971.
20. Hess C, Means TK, Autissier P et al. IL-8 responsiveness defines a subset of CD8 T cells poised to kill. Blood. 2004;104:3463-3471.
21. Jinquan T, Moller B, Storgaard M et al. Chemotaxis and IL-8 receptor expression in B cells from normal and HIV-infected subjects. J Immunol. 1997;158:475-484.
22. Fujii A, Ohshima K, Hamasaki M et al. Differential expression of chemokines, chemokine receptors, cytokines and cytokine receptors in diffuse large B cell malignant lymphoma. Int J Oncol. 2004;24:529-538.
23. Luciani MG, Stoppacciaro A, Peri G et al. The monocyte chemotactic protein 1 (MCP-1) and interleukin 8 (IL-8) in Hodgkin disease and solid tumors. J Clin Pathol. 1998; 51:273-276.
24. Foss HD, Herbst H, Gottstein S et al. Interleukin-8 in Hodgkin's disease: preferential expression by reactive cells and association with neutrophil density. Am J Pathol. 1996;148:1229-1236.
25. Hancock WW, Gao W, Csizmadia V et al. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med. 2001;193:975-980.
26. Sarris AH, Broxmeyer HE, Wirthmueller U et al. Human interferon-inducible protein 10: expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors. J Exp. 1993;178:1127-1132.
27. Luster AD, Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med. 1993;178:1057-1065.
28. Taub DD, Lloyd AR, Conlon K et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med. 1993;177:1809-1814.
29. Maggio EM, van den Berg A, Visser L. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int J Cancer. 2002;99:665-672.
30. Teichmann M, Meyer B, Beck A et al. Expression of the interferon- inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. J Patho. 2005; 22206:68-75.
31. Mazur G, Wróbel T, Butrym A et al. Increased monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in acute myeloid leukemia. Neoplasma. 2007;54:285-289.
32. Husson H, Carideo EG, Cardoso AA et al. MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol. 2001;15:554-562.
33. Giuliani N, Colla S, Rizzoli V. New insight into the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol. 2004;32:685-691.
34. Roodman GD, Choi SJ. Mip-1 alpha and myeloma bone disease. Cancer Treat Res. 2004;118:83-100.
35. Pals ST, de Gorter DJ, Spaargaren M. Lymphoma dissemination: the other face of lymphocyte homing. Blood. 2007;110:3102-3111.
36. Matsuhashi Y, Tasaka T, Uehara E et al. Diffuse large B-cell lymphoma presenting with hypercalcemia and multiple osteolysis. Leuk. Lymphoma. 2004;45:397-400.
37. Bystry RS, Aluvihare V, Welch KA et al. B cells and professional APCs recruit regulatory T cells via CCL 4. Nat Immunol. 2001;2:1126-1132.
38. + T cells in response to MIP-1 alpha and MIP-1 beta. Science. 1993;260:355-358.
39. Ek S, Björck E, Högerkorp CM et al. Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. Int J Cancer. 2006; 118:2092-2097.
40. Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol. 2001;22:83-87.
41. Azenshtein E, Luboshits G, Shina S et al. The CC chemokine RANTES in breast carcinoma progression. Regulation of expression and potential mechanism of promalignant activity. Cancer Res. 2002;62:1093-1102.
42. Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 2006; 66:124-134.
43. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol. 2002;118:915-922.
44. Murooka TT, Wong MM, Rahbar R et al. CCL5-CCR5 mediated apoptosis in T cells: requirement for glycosaminoglycan binding and CCL5 aggregation. J Biol Chem. 2006; 281:25184-25194.
45. Aldinucci D, Lorenzon D, Cattaruzza L et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Cancer. 2008;122:769-776.
46. Virchow R. Die Krankhaften Geschwulste. Hirschwald, Berlin, 1863.
47. Fischer L, Korfel A, Pfeiffer S et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009;15:5968-5973.
48. de Oliveira KB, Oda JM, Voltarelli JC et al. CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. J Clin Lab Anal. 2009;23:387-393.